Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2015)
28 slides from Genetic Signatures's shareholder meeting presentation, Nov 9, 2015
Slide 1: 2015 AGM Presentation
Genetic Signatures 2015 AGM Presentation
Slide 2: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Slide 3: Transforming Molecular Diagnostics
Transforming Molecular Diagnostics Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (in vitro diagnostics) industry with new technology in infection control. Our primary focus is the development and supply of world leading diagnostic solutions to hospitals and
Slide 4: Company Overview
Company Overview § Genetic Signatures provides diagnostic solutions for rapid pathogen detection § Proprietary technology driving product development for pathology and hospital customers globally in multiple markets, with IP protection to 2031 § Products already available in Australia and now launch
Slide 5: Corporate Summary
Corporate Summary Capital Structure ASX Code GSS Shares on Issue 72.9m Market Capitalisation $38m Share Price (at market close 6 November, 2015) $0.525 Cash at 30 September 2015 $5.47m Directors & Chief Executive Nick Samaras Non-Executive Chairman John Melki Director & CEO Mike Aicher Executive Dir
Slide 6: Board and Management
Board and Management Nick Samaras - Non-Executive Chairman BSc (Hons), PhD, MBA, FAIM, FAICD § More than 25 years’ experience in the global life sciences industry, senior executive roles with Applied Biosystems (now part of Thermo Fisher) and Perkin Elmer § NHMRC Research Committee member 2006-12, A
Slide 7: Board and Management
Board and Management Tony Radford- Non-Executive Director BSc (Hons), PhD § A member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics § Co-founded the diagnostic company Cellestis Limited which listed on the ASX in 2001 § Former CEO of Cellestis from found
Slide 8: 2015 Highlights
2015 Highlights Financial Growth § Completed oversubscribed Initial Public Offering (IPO) to raise $7.5 million and list on the Australian Securities Exchange (ASX) § Achieved greater than $1 million in annual sales revenue for the first time in the history of the Company - revenue for FY15 up 52% t
Slide 9: Genetic Signatures: Transforming Global Molecular Diagnostics
Genetic Signatures Transforming Global Molecular Diagnostics 9
Slide 10: Technology - 3Base™
Technology - 3Base™ Platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing. Applicable in testing for infectious diseases and chronic diseases including cancers 10
Slide 11: Technology - 3Base™
Technology - 3Base™ § 3Base™ improves subtype similarity and reduces variation, allowing easier PCR design § e.g, a 10 digit number comprised of the numbers 1,2,3 and 4 has 1,048,576 combinations § a 10 digit number comprised of the numbers 1,2 and 3 has 59,049 combinations § Sufficient information
Slide 12: Technology - 3Base™
Technology - 3Base™ A transformational MDx technology enabling customers to identify a wider array of patient infections § Genetic Signatures’ 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subtypes §
Slide 13: Targeting Critical Health
Targeting Critical Health § Gastroenteritis is a major widespread clinical problem (16.8 million cases per annum in Australia alone) resulting in 250,000 visits to hospital emergency departments, 15,000 hospitalisations and 80 deaths) § Genetic Signatures’ gastroenteritis testing offers faster and m
Slide 14: EasyScreen™ Testing Kits
EasyScreen™ Testing Kits § GSS’ suite of EasyScreen™ products are used by major hospitals in Australia for detection of infectious diseases – 55,000 tests were sold and used in FY15 § Products work with existing customer systems to deliver a wider array of highly specific results in 4-5 hours that w
Slide 15: Case Study: St Vincent's Hospital Evaluation Study
Case Study: St Vincent’s Hospital Evaluation Study - EasyScreen™ vs. Traditional Methods Pathogen Conventional EasyScreen™ METHODS: Methods* § Primary focus of study was to Campylobacter 7 9 assess the clinical utility of Salmonella 8 9 EasyScreen™ in detecting infectious Shigella 5 6 agents in 221
Slide 16: Customer testimonial from Dr Damien Stark
“I find that the fast turnaround time and the number of targets tested in the EasyScreen™ assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.” - Dr Damien Stark 16
Slide 17: EasyScreen™ Product Development Pathway
EasyScreen™ Product Development Pathway Each product goes through extensive development and beta testing and adheres to rigorous quality management systems & regulatory approach. § ISO9001 and ISO13485 certified § Already approved by Australian and European regulators 17
Slide 18: Competitive Advantage
Competitive Advantage § GSS is unique in supplying products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format § Uses latest technology compatible with existing equipment (open platform) § Ease of use and automation § Rapid time to result (<5hrs) § High V
Slide 19: Global Growth Strategy
6 senetic Signatures Global Growth Strategy
Slide 20: 2015 Operational Highlights
2015 Operational Highlights Global Market Reach Expansion § US subsidiary, Genetic Signatures US Ltd incorporated and its US team expanded § Established first European sales channel partnerships with distributors for the regions of Italy and Israel Product Range Expansion § Moved into new state of t
Slide 21: Commercialisation Progress - Australia
Commercialisation Progress - Australia § Currently in market with major hospital and pathology group customers § Australian hospitals and laboratories performed GSS EasyScreen™ tests ~55,000 times in FY15 § Testing for 22 causes of gastroenteritis § Testing for 15 causes of viral respiratory disease
Slide 22: Commercialisation Progress - Europe
Commercialisation Progress - Europe § Established operations in 2013 § Signed Italian distributor and testing with large pathology laboratories, recurrent revenues commencing § Signed Israeli distributor agreement § Increased European sales channel partnership network by signing distribution agreeme
Slide 23: Commercialisation Progress - United States
Commercialisation Progress - United States § Established operations in 2014 with appointment of key personnel § In FY15 GSS achieved first regulatory step towards full product suite commercialisation in the US with receipt of a United States Food and Drug Administration (FDA) listing for a clinical
Slide 24: Immense US Market Potential
Immense US Market Potential § US has 5,686 registered hospitals § Over 900,000 staffed beds § Over 35 million admissions § 3Base™ Technology offers unique advantages for the US Market § High numbers of pathogens detected delivers desirable patient outcomes § Assays available for C. difficile, which
Slide 25: US Market Trends
US Market Trends § Centers for Disease Control and Prevention (CDC) estimates that annually, at least two million illnesses and 23,000 deaths are caused by antibiotic-resistant bacteria in the United States alone § The Infectious Disease Society of America produced a policy paper “Better Tests, Bett
Slide 26: US Market Expansion Approach
US Market Expansion Approach § Discussions underway with Key Opinion Leaders to research Genetic Signatures’ technology § Patient outcome studies – define superior patient care through implementation of broad pathogen screening protocols § Head-to-Head comparison between 3Base™ assays and traditiona
Slide 27: Summary
Summary § EasyScreen™ Respiratory & Enteric Pathogen Detection Kits provide faster & more accurate screening for viral, bacterial and protozoan pathogens – tests are processed in hours instead of days, with fewer false positives and negatives § The 3Base™ platform and products are protected by a pat
Slide 28: Contact: John Melki Chief Executive Officer
Contact: John Melki Chief Executive Officer john@geneticsignatures.com www.geneticsignatures.com 28
Genetic Signatures — Shareholder Meeting (November 2015) on 6ix